Loading companies…
E
Ethris
Germany · Biotech
Ethris develops inhaled mRNA therapeutics and vaccines for respiratory diseases, using proprietary RNA stabilization and nanoparticle delivery platforms.
Product and customers
Ethris is a clinical-stage biotechnology company developing mRNA medicines for respiratory diseases. Its lead candidate, ETH47, is delivered to airway cells by nasal spray or inhalation and instructs them to produce interferon lambda, activating local innate immune defenses against respiratory viruses.
The pipeline targets virus-triggered exacerbations in asthma and COPD as well as broader respiratory-virus preparedness. Ethris also develops mucosal vaccine and RNA-delivery technologies; its September financing supports further clinical development, so these are investigational medicines rather than approved therapies.
- Product focus
- Inhaled mRNA therapeutics for respiratory disease
Funding history
0 rounds · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|
Investors
No participants disclosed.
Coverage
Similar companies
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed
ATAptadir TherapeuticsRNA therapeutics designed to restore expression of silenced genes€40M · Seed